Get more information on Diabetic Neuropathy Market - Request Free Sample Report
The Diabetic Neuropathy Market Size was valued at USD 4.36 billion in 2023 and is witnessed to reach USD 8.38 billion by 2032 and grow at a CAGR of 7.81% over the forecast period 2024-2032.
The market is expanding rapidly due to burgeoning numbers of diabetes sufferers, advances in assays, and novel therapeutics, coupled with rising awareness about chronic complications. The International Diabetes Federation notes that, as of 2022, an estimated 537 million adults around the world between the ages of 20 and 79 have diabetes-approximately a tenth (1 in every ten.) The number is projected to climb to 643 million by 2030 and to a staggering number of around 783 million by the year 2045.
Moreover, since more people are finding the risks and complications of diabetes treating diabetic neuropathy becomes very important. This is expected to increase the number of programs being funded by governments or organized by nonprofit organizations to promote awareness about diabetes. Health initiative - mDiabetes in India A health initiative focused on raising awareness about early diagnosis and treatment of diabetes being launched. Similarly, the World Health Organization and IDF are jointly working against Diabetes to prevent it, control the same & live a better life for people around them. One example is the WHO Diabetes Programme - which aims to prevent type 2 diabetes, reduce complications, and improve disability-free survival and quality of life for people with diabetes. Another normative action is being focused on by several NGOs and governments to promote the prevention of diabetes, raising awareness about risks for diabetes, thus finally making a synergy that can integrate with diabetic disease-specific surveillance too. Thus, strengthening the prevention & control of diabetes.
In addition, there has been a constant evolution in Research and development (R&D) leading to an increase in the diabetic neuropathy treatment market. The article touches on the potential of innovative treatments like gene therapy, stem cell therapy, and targeted drug delivery systems to improve the management or even reverse symptoms of neuropathy. For example, the 2021 study published by NIH is currently underway with a placebo-controlled phase III evaluation of the efficacy and safety of VM202, gene therapy containing plasmid DNA encoding human hepatocyte growth factor for diabetic neuropathy treatment.
This has pushed ahead the cause of growth within the diabetic neuropathy treatment landscape, credited to constant progression in research and development (R&D). So, we're looking for new and innovative treatments like gene therapy, stem cell therapy, or very specific targeted drug delivery systems that would provide not only control but also potentially an ability to improve neuropathy symptoms.
MARKET DYNAMICS:
KEY DRIVERS:
RESTRAINTS:
OPPORTUNITY:
KEY MARKET SEGMENTATION:
By Disorder
Peripheral neuropathy is expected to contribute to the largest revenue share in the global diabetic neuropathy market by disorder type as a result of rising demand from the patients (64.05% in terms of market share) and sales will increase further during the forecast period. The finding, reported in a 2021 NIH study, says that about 2.4% of the entire population have peripheral neuropathy which increases with age group to almost half reaching around the old aged population is turning over at 8%. Over time, this high incidence creates a need for treatments and management options that specifically focus on peripheral neuropathy. In a further study (ScienceDirect Jul 2021), it was evident that the incidence was found to be high in diabetics which equated up to around 40.3%, and type II diabetic patients are more prone than Type I diabetes mellitus.
By Drug Class
The NSAIDs segment led the market in 2023, by drug class with a share of 39.45%. The most common agents for the management of pain in diabetic neuropathy are NSAIDs which give another indication as the first line. NSAIDs reduce inflammation and inhibit prostaglandin synthesis, so they can ease the stiffness requested for relief of pain and diabetic neuropathy. In addition, NSAIDs are available as over-the-counter medicines and tend to be cheaper than other treatments. The fact that they are so readily available helps to make them one of the more appealing options for anyone dealing with diabetic neuropathy. Like, the class of drugs called nonsteroidal anti-inflammatory preparations like ibuprofen and naproxen are helpful in minor-moderate cases associated with pain secondary to diabetic neuropathy.
By Distribution Channel
By distribution channel, the hospital pharmacies segment held a leading position in terms of revenue share at 48.0% in 2023 due to the high prevalence rate of diabetic neuropathy which requires hospitalization. Additionally, it is easy to provide specialized care for patients with diabetic neuropathy because Hospital pharmacies centralize the management of medications within their facility. The centralization means that the necessary medications and treatments are more organized, as well available. Further, government backing in several countries is one of the factors expected to boost growth prospects for the hospital pharmacies segment. For example, the FIP Hospital Pharmacy Section (HPS) is a section dedicated to professional development in hospital pharmacy Practice activities and several proposals & awards were driven by HPL matters. The purpose of the grant is to support cutting-edge research endeavoring in the hospital pharmacy field. The FIP Hospital Pharmacy Section has a strategic plan for 2022-27. Here, this plan defines where hospital pharmacists in different countries can contribute to the FIP Development Goals (DGs) at those levels.
Need any customization research on Diabetic Neuropathy Market - Enquiry Now
REGIONAL COVERAGE:
REGIONAL ANALYSIS:
In 2023, North America was the leader in the diabetic neuropathy treatment market by revenue share constituting 38.01%. Several factors support the market development in the region. The most important is the advanced healthcare infrastructural and high expenditures on healthcare make the area favorable for novel treatments. In addition, some of the market leaders including Abbott, Johnson & Johnson, Eli Lilly, and Pfizer Inc., have their operational companies in this region. Apart from that, the achievement of the Neuralace Medical Painful Diabetic Neuropathy label expansion study with its non-invasive treatment being cleared by the FDA circumstantially might have a transformational effect on the North American market.
KEY PLAYERS:
The Diabetic Neuropathy market players include Abbott, Novartis, Pfizer Inc., Boehringer Ingelheim GmbH, Lupin Pharmaceuticals, Janssen Pharmaceuticals, Inc., Glenmark Pharmaceuticals Ltd., Eli Lilly and Company, Astellas Pharma Inc. & Medtronic PLC & other players.
RECENT DEVELOPMENTS
In July 2023, Asprius Lifesciences, an Indian pharma firm has recently launched the treatment of Diabetic Neuropathy which results in nerve damage to tissues and organs all through entire body areas. FDC patent application submitted, highlighting possibilities in the management of peripheral neuropathy. This will make Asprius a strong contender globally as there is a huge demand for powerful solutions like this.
| Report Attributes | Details |
| Market Size in 2023 | US$ 4.36 Billion |
| Market Size by 2032 | US$ 8.38 Billion |
| CAGR | CAGR of 7.81% From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | •By Disorder Type (Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy, Focal Neuropathy) •By Drug Class (Antidepressants, NSAIDs, Capsaicin, Opioid, Others) •By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Others) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia, Rest of Latin America) |
| Company Profiles | Abbott, Novartis, Pfizer. Inc, Boehringer Ingelheim GmbH, Lupin Pharmaceuticals, Janssen Pharmaceuticals, Inc., Glenmark Pharmaceuticals Ltd., Eli Lilly and Company, Astellas Pharma Inc. & Medtronic PLC & other players |
| Key Drivers | •Surged Cases of Diabetes have Generated the Need for Diabetic Neuropathy Propelling the Market Growth. •The Rising Awareness About Diabetes Complications is Surging Demand for Diabetic Neuropathy Procedures. |
| RESTRAINTS | •Higher Costs for Diabetic Neuropathy Procedures are Hindering the Growth of the Market. •Stringent Government Policies Can Limit the Adoption of Diabetic Neuropathy Procedures. |
Ans: The Diabetic Neuropathy Market is to grow at a CAGR of 7.81% Over the Forecast Period 2024-2032.
Ans: The Diabetic Neuropathy Market size was valued at USD 4.36 Billion in 2023.
Ans. In 2023, North America held the largest market share.
Ans. Pfizer, Inc. is the market's dominant participant.
Ans. The market is likely to be driven by an increase in prevalence, an increase in R&D activities by major players, an increase in pipeline analysis by market participants, new product releases, and other factors.
TABLE OF CONTENTS
1. Introduction
1.1 Market Definition
1.2 Scope
1.3 Research Assumptions
2. Industry Flowchart
3. Research Methodology
4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
5. Porter’s 5 Forces Model
6. Pest Analysis
7. Diabetic Neuropathy Market Segmentation, By Disorder
7.1 Introduction
7.2 Peripheral Neuropathy
7.3 Autonomic Neuropathy
7.4 Proximal Neuropathy
7.5 Focal Neuropathy
8. Diabetic Neuropathy Market Segmentation, By Drug Class
8.1 Introduction
8.2 Capsaicin
8.3 Opioid
8.4 Non-steroidal anti-inflammatory Drugs (NSAIDs)
8.5 Antidepressants
8.6 Others
9. Diabetic Neuropathy Market Segmentation, By Distribution Channel
9.1 Introduction
9.2 Hospitals Pharmacies
9.3 Retail Pharmacies
9.4 Others
10. Regional Analysis
10.1 Introduction
10.2 North America
10.2.1 Trend Analysis
10.2.2 North America Diabetic Neuropathy Market by Country
10.2.3 North America Diabetic Neuropathy Market By Disorder
10.2.4 North America Diabetic Neuropathy Market By Drug Class
10.2.5 North America Diabetic Neuropathy Market By Distribution Channel
10.2.6 USA
10.2.6.1 USA Diabetic Neuropathy Market By Disorder
10.2.6.2 USA Diabetic Neuropathy Market By Drug Class
10.2.6.3 USA Diabetic Neuropathy Market By Distribution Channel
10.2.7 Canada
10.2.7.1 Canada Diabetic Neuropathy Market By Disorder
10.2.7.2 Canada Diabetic Neuropathy Market By Drug Class
10.2.7.3 Canada Diabetic Neuropathy Market By Distribution Channel
10.2.8 Mexico
10.2.8.1 Mexico Diabetic Neuropathy Market By Disorder
10.2.8.2 Mexico Diabetic Neuropathy Market By Drug Class
10.2.8.3 Mexico Diabetic Neuropathy Market By Distribution Channel
10.3 Europe
10.3.1 Trend Analysis
10.3.2 Eastern Europe
10.3.2.1 Eastern Europe Diabetic Neuropathy Market by Country
10.3.2.2 Eastern Europe Diabetic Neuropathy Market By Disorder
10.3.2.3 Eastern Europe Diabetic Neuropathy Market By Drug Class
10.3.2.4 Eastern Europe Diabetic Neuropathy Market By Distribution Channel
10.3.2.5 Poland
10.3.2.5.1 Poland Diabetic Neuropathy Market By Disorder
10.3.2.5.2 Poland Diabetic Neuropathy Market By Drug Class
10.3.2.5.3 Poland Diabetic Neuropathy Market By Distribution Channel
10.3.2.6 Romania
10.3.2.6.1 Romania Diabetic Neuropathy Market By Disorder
10.3.2.6.2 Romania Diabetic Neuropathy Market By Drug Class
10.3.2.6.4 Romania Diabetic Neuropathy Market By Distribution Channel
10.3.2.7 Hungary
10.3.2.7.1 Hungary Diabetic Neuropathy Market By Disorder
10.3.2.7.2 Hungary Diabetic Neuropathy Market By Drug Class
10.3.2.7.3 Hungary Diabetic Neuropathy Market By Distribution Channel
10.3.2.8 Turkey
10.3.2.8.1 Turkey Diabetic Neuropathy Market By Disorder
10.3.2.8.2 Turkey Diabetic Neuropathy Market By Drug Class
10.3.2.8.3 Turkey Diabetic Neuropathy Market By Distribution Channel
10.3.2.9 Rest of Eastern Europe
10.3.2.9.1 Rest of Eastern Europe Diabetic Neuropathy Market By Disorder
10.3.2.9.2 Rest of Eastern Europe Diabetic Neuropathy Market By Drug Class
10.3.2.9.3 Rest of Eastern Europe Diabetic Neuropathy Market By Distribution Channel
10.3.3 Western Europe
10.3.3.1 Western Europe Diabetic Neuropathy Market by Country
10.3.3.2 Western Europe Diabetic Neuropathy Market By Disorder
10.3.3.3 Western Europe Diabetic Neuropathy Market By Drug Class
10.3.3.4 Western Europe Diabetic Neuropathy Market By Distribution Channel
10.3.3.5 Germany
10.3.3.5.1 Germany Diabetic Neuropathy Market By Disorder
10.3.3.5.2 Germany Diabetic Neuropathy Market By Drug Class
10.3.3.5.3 Germany Diabetic Neuropathy Market By Distribution Channel
10.3.3.6 France
10.3.3.6.1 France Diabetic Neuropathy Market By Disorder
10.3.3.6.2 France Diabetic Neuropathy Market By Drug Class
10.3.3.6.3 France Diabetic Neuropathy Market By Distribution Channel
10.3.3.7 UK
10.3.3.7.1 UK Diabetic Neuropathy Market By Disorder
10.3.3.7.2 UK Diabetic Neuropathy Market By Drug Class
10.3.3.7.3 UK Diabetic Neuropathy Market By Distribution Channel
10.3.3.8 Italy
10.3.3.8.1 Italy Diabetic Neuropathy Market By Disorder
10.3.3.8.2 Italy Diabetic Neuropathy Market By Drug Class
10.3.3.8.3 Italy Diabetic Neuropathy Market By Distribution Channel
10.3.3.9 Spain
10.3.3.9.1 Spain Diabetic Neuropathy Market By Disorder
10.3.3.9.2 Spain Diabetic Neuropathy Market By Drug Class
10.3.3.9.3 Spain Diabetic Neuropathy Market By Distribution Channel
10.3.3.10 Netherlands
10.3.3.10.1 Netherlands Diabetic Neuropathy Market By Disorder
10.3.3.10.2 Netherlands Diabetic Neuropathy Market By Drug Class
10.3.3.10.3 Netherlands Diabetic Neuropathy Market By Distribution Channel
10.3.3.11 Switzerland
10.3.3.11.1 Switzerland Diabetic Neuropathy Market By Disorder
10.3.3.11.2 Switzerland Diabetic Neuropathy Market By Drug Class
10.3.3.11.3 Switzerland Diabetic Neuropathy Market By Distribution Channel
10.3.3.12 Austria
10.3.3.12.1 Austria Diabetic Neuropathy Market By Disorder
10.3.3.12.2 Austria Diabetic Neuropathy Market By Drug Class
10.3.3.12.3 Austria Diabetic Neuropathy Market By Distribution Channel
10.3.3.13 Rest of Western Europe
10.3.3.13.1 Rest of Western Europe Diabetic Neuropathy Market By Disorder
10.3.3.13.2 Rest of Western Europe Diabetic Neuropathy Market By Drug Class
10.3.3.13.3 Rest of Western Europe Diabetic Neuropathy Market By Distribution Channel
10.4 Asia-Pacific
10.4.1 Trend Analysis
10.4.2 Asia-Pacific Diabetic Neuropathy Market by Country
10.4.3 Asia-Pacific Diabetic Neuropathy Market By Disorder
10.4.4 Asia-Pacific Diabetic Neuropathy Market By Drug Class
10.4.5 Asia-Pacific Diabetic Neuropathy Market By Distribution Channel
10.4.6 China
10.4.6.1 China Diabetic Neuropathy Market By Disorder
10.4.6.2 China Diabetic Neuropathy Market By Drug Class
10.4.6.3 China Diabetic Neuropathy Market By Distribution Channel
10.4.7 India
10.4.7.1 India Diabetic Neuropathy Market By Disorder
10.4.7.2 India Diabetic Neuropathy Market By Drug Class
10.4.7.3 India Diabetic Neuropathy Market By Distribution Channel
10.4.8 Japan
10.4.8.1 Japan Diabetic Neuropathy Market By Disorder
10.4.8.2 Japan Diabetic Neuropathy Market By Drug Class
10.4.8.3 Japan Diabetic Neuropathy Market By Distribution Channel
10.4.9 South Korea
10.4.9.1 South Korea Diabetic Neuropathy Market By Disorder
10.4.9.2 South Korea Diabetic Neuropathy Market By Drug Class
10.4.9.3 South Korea Diabetic Neuropathy Market By Distribution Channel
10.4.10 Vietnam
10.4.10.1 Vietnam Diabetic Neuropathy Market By Disorder
10.4.10.2 Vietnam Diabetic Neuropathy Market By Drug Class
10.4.10.3 Vietnam Diabetic Neuropathy Market By Distribution Channel
10.4.11 Singapore
10.4.11.1 Singapore Diabetic Neuropathy Market By Disorder
10.4.11.2 Singapore Diabetic Neuropathy Market By Drug Class
10.4.11.3 Singapore Diabetic Neuropathy Market By Distribution Channel
10.4.12 Australia
10.4.12.1 Australia Diabetic Neuropathy Market By Disorder
10.4.12.2 Australia Diabetic Neuropathy Market By Drug Class
10.4.12.3 Australia Diabetic Neuropathy Market By Distribution Channel
10.4.13 Rest of Asia-Pacific
10.4.13.1 Rest of Asia-Pacific Diabetic Neuropathy Market By Disorder
10.4.13.2 Rest of Asia-Pacific Diabetic Neuropathy Market By Drug Class
10.4.13.3 Rest of Asia-Pacific Diabetic Neuropathy Market By Distribution Channel
10.5 Middle East & Africa
10.5.1 Trend Analysis
10.5.2 Middle East
10.5.2.1 Middle East Diabetic Neuropathy Market by Country
10.5.2.2 Middle East Diabetic Neuropathy Market By Disorder
10.5.2.3 Middle East Diabetic Neuropathy Market By Drug Class
10.5.2.4 Middle East Diabetic Neuropathy Market By Distribution Channel
10.5.2.5 UAE
10.5.2.5.1 UAE Diabetic Neuropathy Market By Disorder
10.5.2.5.2 UAE Diabetic Neuropathy Market By Drug Class
10.5.2.5.3 UAE Diabetic Neuropathy Market By Distribution Channel
10.5.2.6 Egypt
10.5.2.6.1 Egypt Diabetic Neuropathy Market By Disorder
10.5.2.6.2 Egypt Diabetic Neuropathy Market By Drug Class
10.5.2.6.3 Egypt Diabetic Neuropathy Market By Distribution Channel
10.5.2.7 Saudi Arabia
10.5.2.7.1 Saudi Arabia Diabetic Neuropathy Market By Disorder
10.5.2.7.2 Saudi Arabia Diabetic Neuropathy Market By Drug Class
10.5.2.7.3 Saudi Arabia Diabetic Neuropathy Market By Distribution Channel
10.5.2.8 Qatar
10.5.2.8.1 Qatar Diabetic Neuropathy Market By Disorder
10.5.2.8.2 Qatar Diabetic Neuropathy Market By Drug Class
10.5.2.8.3 Qatar Diabetic Neuropathy Market By Distribution Channel
10.5.2.9 Rest of Middle East
10.5.2.9.1 Rest of Middle East Diabetic Neuropathy Market By Disorder
10.5.2.9.2 Rest of Middle East Diabetic Neuropathy Market By Drug Class
10.5.2.9.3 Rest of Middle East Diabetic Neuropathy Market By Distribution Channel
10.5.3 Africa
10.5.3.1 Africa Diabetic Neuropathy Market by Country
10.5.3.2 Africa Diabetic Neuropathy Market By Disorder
10.5.3.3 Africa Diabetic Neuropathy Market By Drug Class
10.5.3.4 Africa Diabetic Neuropathy Market By Distribution Channel
10.5.3.5 Nigeria
10.5.3.5.1 Nigeria Diabetic Neuropathy Market By Disorder
10.5.3.5.2 Nigeria Diabetic Neuropathy Market By Drug Class
10.5.3.5.3 Nigeria Diabetic Neuropathy Market By Distribution Channel
10.5.3.6 South Africa
10.5.3.6.1 South Africa Diabetic Neuropathy Market By Disorder
10.5.3.6.2 South Africa Diabetic Neuropathy Market By Drug Class
10.5.3.6.3 South Africa Diabetic Neuropathy Market By Distribution Channel
10.5.3.7 Rest of Africa
10.5.3.7.1 Rest of Africa Diabetic Neuropathy Market By Disorder
10.5.3.7.2 Rest of Africa Diabetic Neuropathy Market By Drug Class
10.5.3.7.3 Rest of Africa Diabetic Neuropathy Market By Distribution Channel
10.6 Latin America
10.6.1 Trend Analysis
10.6.2 Latin America Diabetic Neuropathy Market by country
10.6.3 Latin America Diabetic Neuropathy Market By Disorder
10.6.4 Latin America Diabetic Neuropathy Market By Drug Class
10.6.5 Latin America Diabetic Neuropathy Market By Distribution Channel
10.6.6 Brazil
10.6.6.1 Brazil Diabetic Neuropathy Market By Disorder
10.6.6.2 Brazil Diabetic Neuropathy Market By Drug Class
10.6.6.3 Brazil Diabetic Neuropathy Market By Distribution Channel
10.6.7 Argentina
10.6.7.1 Argentina Diabetic Neuropathy Market By Disorder
10.6.7.2 Argentina Diabetic Neuropathy Market By Drug Class
10.6.7.3 Argentina Diabetic Neuropathy Market By Distribution Channel
10.6.8 Colombia
10.6.8.1 Colombia Diabetic Neuropathy Market By Disorder
10.6.8.2 Colombia Diabetic Neuropathy Market By Drug Class
10.6.8.3 Colombia Diabetic Neuropathy Market By Distribution Channel
10.6.9 Rest of Latin America
10.6.9.1 Rest of Latin America Diabetic Neuropathy Market By Disorder
10.6.9.2 Rest of Latin America Diabetic Neuropathy Market By Drug Class
10.6.9.3 Rest of Latin America Diabetic Neuropathy Market By Distribution Channel
11. Company Profiles
11.1 Abbott
11.1.1 Company Overview
11.1.2 Financial
11.1.3 Disorder s/ Services Offered
11.1.4 The SNS View
11.2 Novartis
11.2.1 Company Overview
11.2.2 Financial
11.2.3 Disorder s/ Services Offered
11.2.4 The SNS View
11.3 Pfizer. Inc.
11.3.1 Company Overview
11.3.2 Financial
11.3.3 Disorder s/ Services Offered
11.3.4 The SNS View
11.4 Boehringer Ingelheim GmbH
11.4.1 Company Overview
11.4.2 Financial
11.4.3 Disorder s/ Services Offered
11.4.4 The SNS View
11.5 Lupin Pharmaceuticals
11.5.1 Company Overview
11.5.2 Financial
11.5.3 Disorder s/ Services Offered
11.5.4 The SNS View
11.6 Janssen Pharmaceuticals, Inc.
11.6.1 Company Overview
11.6.2 Financial
11.6.3 Disorder s/ Services Offered
11.6.4 The SNS View
11.7 Glenmark Pharmaceuticals Ltd.
11.7.1 Company Overview
11.7.2 Financial
11.7.3 Disorder s/ Services Offered
11.7.4 The SNS View
11.8 Eli Lilly and Company
11.8.1 Company Overview
11.8.2 Financial
11.8.3 Disorder s/ Services Offered
11.8.4 The SNS View
11.9 Astellas Pharma Inc.
11.9.1 Company Overview
11.9.2 Financial
11.9.3 Disorder s/ Services Offered
11.9.4 The SNS View
11.10 Medtronic PLC
11.10.1 Company Overview
11.10.2 Financial
11.10.3 Disorder s/ Services Offered
11.10.4 The SNS View
12. Competitive Landscape
12.1 Competitive Benchmarking
12.2 Market Share Analysis
12.3 Recent Developments
12.3.1 Industry News
12.3.2 Company News
12.3.3 Mergers & Acquisitions
13. Use Case and Best Practices
14. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
The Biosimilars Market size was valued at USD 29.51 Billion in 2023 and is expected to reach USD 108.8 Billion By 2031 and grow at a CAGR of 17.7% over the forecast period of 2024-2031.
The Teeth Whitening Market size was estimated USD 7.1 billion in 2022 and is expected to reach USD 10.5 billion by 2030 at a CAGR of 5.1% during the forecast period of 2023-2030.
The Dental Lasers Market size was estimated at USD 262.23 billion in 2023 and is expected to reach USD 396.38 billion by 2031 with a growing CAGR of 5.3% during the forecast period of 2024-2031.
The Pancreatic and Biliary Stents Market was valued at USD 354.2 Mn in 2023 and is expected to reach 511.47 Mn in 2031, and grow at a CAGR of 4.7% over the forecast period of 2024-2031.
The Cell Freezing Media Market size was estimated at USD 141.3 million in 2022 and is expected to reach USD 296.3 million by 2030 with a growing CAGR of 9.7% during the forecast period of 2023-2030.
The Bioremediation Market size was estimated at USD 14.95 billion in 2023 and is expected to reach USD 34.27 billion by 2032 with a growing CAGR of 9.69% during the forecast period of 2024-2032.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
